| Schedule of research and development expenses |
| Schedule of research and development expenses | |
| | | |
| | | |
| | | |
| | |
| | |
Three Months Ended June 30, | |
Six Months Ended June 30, |
| | |
2026 | |
2025 | |
2026 | |
2025 |
| Personnel and consulting expenses | |
$ | 1,031,747 | | |
$ | 858,546 | | |
$ | 2,240,958 | | |
$ | 1,715,239 | |
| External clinical study expenses | |
| 772,019 | | |
| 1,521,617 | | |
| 1,353,208 | | |
| 3,355,988 | |
| Nonclinical and biomarker research | |
| 197,323 | | |
| 250,811 | | |
| 735,400 | | |
| 343,212 | |
| Chemistry Manufacturing & Control (“CMC”) related costs | |
| 65,736 | | |
| 133,831 | | |
| 302,503 | | |
| 570,685 | |
| Total research and development expenses | |
$ | 2,066,825 | | |
$ | 2,764,805 | | |
$ | 4,632,069 | | |
$ | 5,985,124 | |
|